Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...
7000 Shoreline Court
South San Francisco, CA 94080
Founded in 2006
Veracyte, Inc. Appoints Dr. Neil M. Barth as Chief Medical Officer
Aug 17 15
Veracyte, Inc. announced the appointment of Neil M. Barth, M.D., F.A.C.P., as chief medical officer, effective immediately.
Dr. Barth has more than 30 years of experience providing and directing patient care for healthcare-provider
organizations and diagnostics companies. Most recently, he served as chief medical officer for Agendia NV. Prior to that, Dr. Barth served as chief medical officer for Ambry Genetics.
Veracyte, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2015 ; Reiterates Guidance for the Year 2015
Aug 13 15
Veracyte, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of $11,908,000, loss from operations of $9,074,000, net loss and comprehensive loss of $9,136,000 or $0.35 per basic and diluted share compared to the revenue of $8,677,000, loss from operations of $6,561,000, net loss and comprehensive loss of $6,655,000 or $0.31 per basic and diluted share for the same quarter a year ago.
For the six months period, the company reported revenue of $23,126,000, loss from operations of $16,627,000, net loss and comprehensive loss of $16,746,000 or $0.69 per basic and diluted share compared to the revenue of $16,153,000, loss from operations of $13,136,000, net loss and comprehensive loss of $13,329,000 or $0.63 per basic and diluted share for the same period a year ago.
The company reiterated its 2015 annual revenue guidance of $48 million to $53 million, as well as its forecast to achieve annual Afirma GEC test volume in the range of 19,000 to 21,000.
Veracyte, Inc. to Report Q2, 2015 Results on Aug 13, 2015
Aug 6 15
Veracyte, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 13, 2015